-
Je něco špatně v tomto záznamu ?
Allergen bronchoprovocation test: an important research tool supporting precision medicine
LP. Boulet, A. Côté, K. Abd-Elaziz, G. Gauvreau, Z. Diamant
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
- MeSH
- alergeny imunologie MeSH
- bronchiální astma diagnóza imunologie MeSH
- bronchoprovokační testy metody MeSH
- fenotyp MeSH
- individualizovaná medicína metody MeSH
- lidé MeSH
- respirační funkční testy metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
PURPOSE OF REVIEW: Allergen bronchoprovocation test (ABT) has been used to study asthma pathophysiology and as a disease-modelling tool to assess the properties and efficacy of new asthma drugs. In view of the complexity and heterogeneity of asthma, which has driven the definition of several phenotypes and endotypes, we aim to discuss the role of ABT in the era of precision medicine and provide guidance for clinicians how to interpret and use available data to understand the implications for the benefits of asthma treatment. RECENT FINDINGS: In this review, we summarize background knowledge and applications of ABT and provide an update with recent publications on this topic. In the past years, several studies have been published on ABT in combination with non-invasive and invasive airway samplings and innovative detection techniques allowing to study several inflammatory mechanisms linked to Th2-pathway and allergen-induced pathophysiology throughout the airways. SUMMARY: ABT is a valuable research tool, which has strongly contributed to precision medicine by helping to define allergen-triggered key inflammatory pathways and airway pathophysiology, and thus helped to shape our understanding of allergen-driven asthma phenotypes and endotypes. In addition, ABT has been instrumental to assess the interactions and effects of new-targeted asthma treatments along these pathways.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026235
- 003
- CZ-PrNML
- 005
- 20211026133105.0
- 007
- ta
- 008
- 211013s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MCP.0000000000000742 $2 doi
- 035 __
- $a (PubMed)33065599
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Boulet, Louis-Philippe $u Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart and Lung Institute, Université Laval, Québec, Canada
- 245 10
- $a Allergen bronchoprovocation test: an important research tool supporting precision medicine / $c LP. Boulet, A. Côté, K. Abd-Elaziz, G. Gauvreau, Z. Diamant
- 520 9_
- $a PURPOSE OF REVIEW: Allergen bronchoprovocation test (ABT) has been used to study asthma pathophysiology and as a disease-modelling tool to assess the properties and efficacy of new asthma drugs. In view of the complexity and heterogeneity of asthma, which has driven the definition of several phenotypes and endotypes, we aim to discuss the role of ABT in the era of precision medicine and provide guidance for clinicians how to interpret and use available data to understand the implications for the benefits of asthma treatment. RECENT FINDINGS: In this review, we summarize background knowledge and applications of ABT and provide an update with recent publications on this topic. In the past years, several studies have been published on ABT in combination with non-invasive and invasive airway samplings and innovative detection techniques allowing to study several inflammatory mechanisms linked to Th2-pathway and allergen-induced pathophysiology throughout the airways. SUMMARY: ABT is a valuable research tool, which has strongly contributed to precision medicine by helping to define allergen-triggered key inflammatory pathways and airway pathophysiology, and thus helped to shape our understanding of allergen-driven asthma phenotypes and endotypes. In addition, ABT has been instrumental to assess the interactions and effects of new-targeted asthma treatments along these pathways.
- 650 _2
- $a alergeny $x imunologie $7 D000485
- 650 _2
- $a bronchiální astma $x diagnóza $x imunologie $7 D001249
- 650 _2
- $a bronchoprovokační testy $x metody $7 D001985
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a fenotyp $7 D010641
- 650 _2
- $a individualizovaná medicína $x metody $7 D057285
- 650 _2
- $a respirační funkční testy $x metody $7 D012129
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Côté, Andréanne $u Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec Heart and Lung Institute, Université Laval, Québec, Canada
- 700 1_
- $a Abd-Elaziz, Khalid $u QPS-Netherlands, Groningen, The Netherlands
- 700 1_
- $a Gauvreau, Gail $u Department of Medicine, McMaster University, Hamilton, Ontario, Canada
- 700 1_
- $a Diamant, Zuzana $u Department of Respiratory Medicine and Allergology, Institute for Clinical Science, Skane University Hospital, Lund University, Lund, Sweden $u Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic $u Department Clinical Pharmacy and Pharmacology, University Groningen, University Medicine Ctr Groningen, Groningen, The Netherlands
- 773 0_
- $w MED00005060 $t Current opinion in pulmonary medicine $x 1531-6971 $g Roč. 27, č. 1 (2021), s. 15-22
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33065599 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133111 $b ABA008
- 999 __
- $a ok $b bmc $g 1715062 $s 1146742
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 27 $c 1 $d 15-22 $e - $i 1531-6971 $m Current opinion in pulmonary medicine $n Curr. Opin. Pulm. Med. $x MED00005060
- LZP __
- $a Pubmed-20211013
